Cushing's Syndrome Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

2021-07-05 06:04:50

(MENAFN- GetNews)“Cushing’s Syndrome Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cushing’s Syndrome market. A detailed picture of the Cushing’s Syndrome pipeline landscape is provided, which includes the disease overview and Cushing’s Syndrome treatment guidelines.

DelveInsight’s “ Cushing’s Syndrome Pipeline Insight ” report provides comprehensive insights about key companies and pipeline drugs in the Cushing’s Syndrome pipeline landscapes. It comprises Cushing’s Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cushing’s Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cushing’s Syndrome pipeline products.

Some of the key takeaways of the Cushing’s Syndrome Pipeline Report

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Recordati, Corcept Therapeutics, Millendo Therapeutics, Cortendo, SteroTherapeutics, etc., are developing therapies for the treatment of Cushing’s Syndrome.
Emerging therapies such as Osilodrostat, Relacorilant, ATR-101, Levoketoconazole, ST-002, are expected to have a significant impact on the Cushing’s Syndrome market in the coming years.
Osilodrostat is an orally administered steroidogenesis inhibitor of 11Beta-hydroxylase, an enzyme that catalyses the final step of cortisol synthesis in the adrenal cortex. This molecule is currently in Phase III of clinical development.

Get an overview of pipeline landscape @ Cushing’s Syndrome Clinical Trials Analysis

Cushing’s syndrome (CS) is a rare problem caused when the adrenal gland(s) makes too much of a hormone called cortisol. CS is most often due to a tumour or mass found in the pituitary gland, but can also be caused by tumours in the adrenal glands themselves.

Cushing’s Syndrome Emerging Drugs

Osilodrostat by Recordati

Relacorilant by Corcept Therapeutics

ATR-101 by Millendo Therapeutics

Levoketoconazole by Cortendo

ST-002 by SteroTherapeutics

For further information, refer to the detailed report @ Cushing’s Syndrome Pipeline Therapeutics

Scope of Cushing’s Syndrome Pipeline Drug Insight

Coverage: Global
Major Players: Recordati, Corcept Therapeutics, Millendo Therapeutics, Cortendo, SteroTherapeutics, and others.
Pipeline Therapies: Osilodrostat, Relacorilant, ATR-101, Levoketoconazole, ST-002, and others.

Table of Contents

1	Cushing’s Syndrome Report Introduction
2	Cushing’s Syndrome Executive Summary
3	Cushing’s Syndrome Overview
4	Cushing’s Syndrome- Analytical Perspective In-depth Commercial Assessment
5	Cushing’s Syndrome Pipeline Therapeutics
6	Cushing’s Syndrome Late Stage Products (Phase II/III)
7	Cushing’s Syndrome Mid Stage Products (Phase II)
8	Cushing’s Syndrome Early Stage Products (Phase I)
9	Cushing’s Syndrome Preclinical Stage Products
10	Cushing’s Syndrome Therapeutic Assessment
11	Cushing’s Syndrome Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Cushing’s Syndrome Key Companies
14	Cushing’s Syndrome Key Products
15	Cushing’s Syndrome Unmet Needs
16	Cushing’s Syndrome Market Drivers and Barriers
17	Cushing’s Syndrome Future Perspectives and Conclusion
18	Cushing’s Syndrome Analyst Views
19	Appendix
20	About DelveInsight

MENAFN05072021003238003268ID1102397296

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.